T. Friedl

发表

The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial

M. Beckmann, P. Fasching, T. Fehm, 2017, PloS one.

Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study

M. Kiechle, N. Harbeck, J. Huober, 2016, British Journal of Cancer.

Abstract P3-12-09: The prevalence and quantity of circulating tumor cells (CTCs) after adjuvant chemotherapy with and without anthracyclines in patients with HER2-negative early breast cancer (EBC)

M. Beckmann, P. Fasching, T. Fehm, 2013 .

Pelvic exenteration as ultimate ratio for gynecologic cancers: single-center analyses of 37 cases

F. Ebner, P. Widschwendter, J. Huober, 2019, Archives of Gynecology and Obstetrics.

Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program

T. Fehm, D. Wallwiener, K. Pantel, 2021, ESMO open.

Prognostic factors for and pattern of lymph-node involvement in patients with operable cervical cancer

P. Widschwendter, W. Janni, C. Scholz, 2019, Archives of Gynecology and Obstetrics.

Abstract PD6-6: A pooled analysis of the prognostic relevance of circulating tumor cells in early breast cancer

P. Fasching, T. Fehm, A. Lucci, 2013 .

Abstract P1-12-03: Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer – Results from the prospective multi-center randomized Adebar trial

M. Kiechle, N. Harbeck, J. Huober, 2016 .

Hypotension due to spinal anesthesia influences fetal circulation in primary caesarean sections

P. Widschwendter, W. Janni, K. Lato, 2018, Archives of Gynecology and Obstetrics.

Abstract GS1-06: Extended adjuvant bisphosphonate treatment over five years in early breast cancer does not improve disease-free and overall survival compared to two years of treatment: Phase III data from the SUCCESS A study

M. Beckmann, T. Fehm, A. Schneeweiss, 2018 .

Abstract S2-03: Persistence of circulating tumor cells in high risk early breast cancer patients during follow-up care suggests poor prognosis – Results from the adjuvant SUCCESS A trial

M. Beckmann, P. Fasching, T. Fehm, 2016 .

Abstract GS5-03: Lifestyle Intervention and Effect on Disease-free Survival in Early Breast Cancer Pts: Interim Analysis from the Randomized SUCCESS C Study

M. Rezai, M. Beckmann, L. Häberle, 2019, General Session Abstracts.

Diagnosis of presence and extent of deep infiltrating endometriosis by preoperative MRI-improvement of staging accuracy by expert training.

P. Widschwendter, W. Janni, T. Friedl, 2021, Journal of gynecology obstetrics and human reproduction.

Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial

M. Rezai, M. Beckmann, P. Fasching, 2016, Geburtshilfe und Frauenheilkunde.

Does Non-Placement of a Drain in Breast Surgery Increase the Rate of Complications and Revisions?

A. Rempen, F. Ebner, W. Janni, 2013, Geburtshilfe und Frauenheilkunde.

Abstract P3-12-09: The prevalence and quantity of circulating tumor cells (CTCs) after adjuvant chemotherapy with and without anthracyclines in patients with HER2-negative early breast cancer (EBC)

M. Beckmann, P. Fasching, T. Fehm, 2013 .